We are pleased to announce our company’s participation at CHINA Bio 2023, from September 20 – 21, 2023, in Shanghai, China. Our Chairwoman, Revital Rattenbach, and our CEO, Didier Landais, and Francis Berenbaum, CEO/CMO of our subsidiary, 4Moving Biotech, will attend this event. During the event, Pr. Francis Berenbaum will showcase our subsidiary, 4Moving&hellip
We are delighted to announce the appointment of Didier Landais as the CEO of 4P-Pharma. Didier Landais brings a wealth of experience and strategic leadership to our team. His dynamic vision and profound insights will drive 4P-Pharma into an era of innovation and growth. Find the press release in English here.
Meet us in Boston during the Bio US 2023, June 5th to 8th! Roselina Lam, our Business Development and Licensing-in Manager, will be participating at the event, part of the french healthcare delegation ! Schedule a meeting with us !
4P-Pharma is delighted to welcome Mathilde Mérot appointed Director of Regulatory Affairs and Clinical Operations. She has ten years of experience and a background in Pharma and Biotech companies. Her expertise will complement ours to develop and bring curative therapies for serious untreated diseases to patients. About Mathilde Mérot Mathilde Mérot started her career in clinical&hellip
Our subsidiary 4Moving Biotech, was presented at OARSI- World Congress on Osteoarthritis. It was an excellent opportunity to share our subsidiary’s latest progress and development. Our subsidiary Co-founder/CMO Pr. Francis Berenbaum showcased two posters during the OARSI congress. First poster at OA clinical trial symposium on March 16, 2023 Poster title: GLP1 analogues as a&hellip
We are delighted to announce that Pr. Francis Berenbaum, Co-founder and CEO/CMO of our subsidiary 4Moving Biotech, is attending from March 19th-24th,2023, at Gordon Research Conference in Luca, Bragia, Italia as an invitedspeaker. His poster title is Glucagon-like Peptide-1 Analogues: Metabolic Roles and Beyond